Characterization of Melanin-concentrating Hormone Receptor Desensitization by Goodspeed, Andrew E.
The College at Brockport: State University of New York
Digital Commons @Brockport
Biology Master’s Theses Department of Biology
6-2013
Characterization of Melanin-concentrating
Hormone Receptor Desensitization
Andrew E. Goodspeed
The College at Brockport
Follow this and additional works at: https://digitalcommons.brockport.edu/bio_theses
Part of the Biology Commons, and the Cell and Developmental Biology Commons
This Thesis is brought to you for free and open access by the Department of Biology at Digital Commons @Brockport. It has been accepted for
inclusion in Biology Master’s Theses by an authorized administrator of Digital Commons @Brockport. For more information, please contact
kmyers@brockport.edu.
Repository Citation
Goodspeed, Andrew E., "Characterization of Melanin-concentrating Hormone Receptor Desensitization" (2013). Biology Master’s
Theses. 83.
https://digitalcommons.brockport.edu/bio_theses/83
Characterization of Melanin-concentrating Hormone 
Receptor Desensitization 
by 
Andrew E Goodspeed 
A thesis submitted to the Department of Biology of the State University of New 
York College at Brockport in partial fulfillment of the requirements for the 
degree of 
Master of Biology 
June 10th 2013 
The College at 
BROCKPORT 
STATE UNIVERSITY OF NEW YORK 
Department of Biology 
Thesis Defense 
Date: 1lUL)...._ /012.D /) 
Committee Members Approved Not Approved Comment 
- ~e.~ajor Advisor (A~ I 
~ fj /J_;_Committee Member 
G., ;IL Graduate Director: 
-----~-----
Depa rt men t Chair: --f-~~--q-+·~L~-'c:c:-, 
350 New Campus Drive • Brockport, New York 14420-2973 • 585-395-2193 • Fax: 585-395-2741 • www.brockport.edu/biology 
Acknowledgements 
My family has always been extremely supportive and interested in whatever 
my current endower was and my thesis work would not have been possible without 
their continued support. 
From the moment I stepped foot on Brockport' s campus, Dr. Laurie Cook 
took me under her wing and showed me the type scientist I now hope to become. No 
one could ask for a better mentor and I will forever be in her debt. 
1 
Table of Contents 
Abstract ......... ..................... ................. .......... ...... ................... ... .............. ....................... ! 
Introduction ........... .......... .. .............. ..... ... .... ...... ...... .. ................ ........... ................ .......... 3 
Obesity ... .. .. ... ..... .... ..... .. ................................. ...... .. .. .... : ... ... .................. ....... .... .......... 3 
G Protein-coupled Receptors ..... ... ...... ...................................................................... . 5 
GPCR Activation .. ..... ... ............... .......................................... ... .... ..... ... .................. .... 6 
GPCR Desensitization and Resensitization ................................................................ 8 
MCH ..... ............... .. .................... ....................... .............. ...................... .................. .. 13 
MCHRl .... .. ................... ... ....................................................... ... ........... .......... .. ....... 14 
ERK Pathway ...... .. ... .... .. ................ ................... ............... ............................... .. ........ 14 
MCHRl and Obesity ...... ..... ... ........ ....... .... .......... .............. ............ ...... ...... ....... ........ 15 
Specific Aims ....... ..... ... .. ... .. ... .... ... ............................... ..... ...................... ..... ....... ..... 16 
Materials and Methods ...... ..... .... .............. .......... .................... , ..................................... 1 7 
Tissue Culture ................ .. ........ ............................................. .... ........ .... ... .... ... ....... .. 17 
Transfection .... .. .............. ... ............... ......... .............. ........ .... ... ..... ............ ... .... .. ..... ... 17 
Cell Based ELISA ........................................... .. .......................................... ............. 1 7 
Multiple MCH Treatments ......... ................................. .. .... ................... ............ ... ..... 18 
Cell L ysate Harvesting for ERK .......... .... .. ........... ........ .... .................................. .. .. .19 
Cell Lysate Harvesting for MCHRl .. ............... .................................... .................... 19 
SDS-PAGE ............................................................................................................... 19 
Semi-dry Transfer ....................... ........ ... ... ....... ..... ... ... ................ .. ... ........ ................ 20 
Wet Transfer ... ...... ........ .. ...... ... ...... ....... .. ........ ............... .......... ................................. 20 
Western Blot .............................. .. ..................... ...... .. ........................ ... ..................... 20 
Results ................... ..... ............. ........................................... .. ........... ........... .. .... ....... .. ... 22 
MCHRl Activation ..... ... ..................... .... ............. .......... .......................................... 24 
MCHRl Desensitization .. .. ... .. ..... ... ... ... .......... ............... ..... ...... .. ............................. 24 
MCHRl Resensitization ... .... .................................................. .................................. 28 
Changes in MCHRl Protein Levels ....... ....... ................. ....... .. ....... ....................... ... 30 
MCHRl Intemalization ... ....... .............. ................ .... ... .. ..... ..... ...... .... ....................... 32 
Role of GRK.2 in MCHRl Desensitization .................................................. .... .... ... . 35 
ERK Desensitization .. .................. ....... ........ .. ........................................ ........... ..... .. . 39 
Discussion .. ... .. ...... .. ......................... .. .......................................................................... 43 
Verifying MCHRl-mediated ERK Desensitization ...... ..... .... ............ ..... ... ............. .43 
MCHRl Resensitization ........... .... ... ........ ....... ................ .. ............. .......................... .47 
Mechanism of MCHRl Desensitization .... ... .. ... .. .. ... .... .................. ... ...................... 50 
Homologous or Heterologous ERK Desensitization .......... ................................. ... .. 55 
Bibliography ... .. ..................... .... ...... .................. ...... .................. ......... ............. .... ........ 60 
11 
List of Figures 
Figure 1: G Protein-coupled Receptor Signaling ................ .. ......................................... 7 
Figure 2: Limited Restimulation of ERK Following an Initial MCH Treatment ... .... .25 
Figure 3: ERK Pathway Desensitization in 3T3-Ll Cells via MCH .. .... ..... ........... .. ... 27 
Figure 4: MCHRl Desensitization Lasts At Least 70 Minutes ....................... ............ 29 
Figure 5: Long-term Treatment of Cells with MCH Increases Receptors ............... .... 31 
Figure 6: Limited MCH-mediated MCHRl Internalization with GRK5 .......... ....... .... 33 
Figure 7: Limited MCHRl Internalization with GRK3 and GRK2-K220L ... .... ... .... .. 34 
Figure 8: ERK Activation via MCH Treatment with GRK2 DN ...... ... ..... ... ..... .......... 36 
Figure 9: GRK2 Dominant Negative Decreases ERK Pathway Desensitization .... .... 38 
Figure 10: MCHR2 Desensitization Similar to MCHRl .................... ...... ... .. ...... .. .... . .40 
Figure 11: ERK Pathway Desensitization with Isoproterenol Treatment .... ......... ...... .42 
Figure 12: Does GRK2 act at the Receptor Level or Pathway Level? ........................ 56 
111 
Abstract 
Melanin-concentrating hormone (MCH) receptor I-knockout mice have limited 
incidence of diet-induced obesity. This makes the MCH signaling pathway a potential 
pharmacological target to fight human obesity. MCHRl is a G-protein coupled 
receptor (GPCR) that activates multiple signaling pathways, including ERK 
phosphorylation. Overstimulation of GPCR signaling is a hallmark of many diseases. 
Likewise, inadequate desensitization of MCH signaling could potentiate the obese 
phenotype. GPCR desensitization typically involves agonist-induced internalization 
of activated receptors, and subsequent degradation or receptor recycling. The broad 
aim of this study was to determine the length and intensity of ERK phosphorylation 
and it's desensitization to MCHRl activation by MCH. In order to measure this, we 
maximally stimulated 1'.1CHR1-tra_11sfected BHK-570 cells with 100 nM MCH for 10 
min, then following three washes in serum-free media and a 30 min recovery period, 
cells were stimulated again. Western blots of lysates for phosphorylated-ERK and 
total ERK were performed. ImageJ was used to normalize activation levels. MCH 
was unable to signal a second round of ERK signaling unless we waited 70 minutes, 
indicating that the MCH signaling pathway is desensitized during this period. We 
hypothesized that MCHRl internalization was responsible; however using a cell-
based ELISA, we only measured a 15% loss of surface MCHRl after 30 min ofMCH 
treatment. We tested the hypothesis that G protein-coupled receptor kinases were 
limiting factors in preventing agonist-mediated endocytosis ofMCHRl however none 
showed significant gains in internalization. We conclude that MCHRl can undergo 
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receptor-mediated endocytosis, but the fraction of available receptors on the plasma 
membrane does not account for the extensive loss of ERK signaling observed. We 
also tested the effect that a GRK2 dominant negative would have on MCHRI 
desensitization. In a co-transfected BHK-570 model, we did not observe 
desensitization if GRK2 is not present. This suggests that GRK2 is necessary for 
MCHRl desensitization at the plasma membrane. We have also observed similar 
ERK desensitization following both isoproterenol treatment and MCHR2 activation 
which could suggest that simply the ERK pathway desensitizing is being observed 
which could be independent of the agonist. This study suggests that MCH-mediated 
ERK signaling desensitizes while MCHRl is at the plasma membrane, rather than via 
removal of the receptor from the cell surface. Future experiments will be aimed at 
determining whether this ERK pathway desensitization is homologous or 
heterologous in addition to observing downstream pathways ofMCHRl activation 
other than ERK. 
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Introduction 
Obesity 
Obesity is now a national pandemic that does not only affect the United States but 
many other portions of the world. This pandemic has been brought about only in the 
last century as a result of our modem society developing. For the majority of the last 
century, food has been relatively inexpensive and easy to come by for most of the 
world. In addition to easy food access, the rise in high calorie foods and fast food 
restaurants has increased caloric intake more than what is needed to survive. Add in 
the fact that technology has removed much of the physical labor that was once needed 
to survive and aU of the pieces of an obesity pandemic are in place (Pi-Sunyer, 2002). 
The development of obesity is driven by an abnormal balance between food 
intake and energy expenditure, when food intake is higher than the latter. Obesity is 
defined as having a body mass index (BMI) of 30 kg/m2 or higher which currently 
affects almost 500 million adults and 40-50 million children worldwide (Kral, 2012). 
Even more troublesome than the vast number of individuals that are defined as obese 
is the current trends related to obesity. A 30 year study in Sweden, conducted by 
Neovius et al. that ended in 2005, found there was a 5-fold increase in obesity among 
young adult men and estimated that by 2020, 4% of the adult population will be 
severely obese (Neovius, 2008). The Center for Disease Control and Prevention 
determined that between 2009 and 2010, 35.7% of the United States adults were 
obese. Obesity in children and adolescents was recorded at an alarming 16.7% during 
this time (Pi-Sunyer, 2002). 
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The increase in obesity has severe consequences both in regards to health and 
finances. Elevated BMI has been shown to increase the development of many 
diseases which often have high morbidity and mortality. These diseases include, but 
are certainly not limited to, insulin resistance, type 2 diabetes, hypertension, coronary 
heart disease and gallbladder disease (Pi-Sunyer, 2002). If preventing the 
development of these diseases is not enough motivation to fight obesity, its economic 
impact may be. 
The US health care spending difference from normal weight adults and obese 
adults increased from 8 to 38% from 1987 to 2007 (Davies, G. et al., 2010). An 
analysis by the Office of Health Economics in England concluded that 5% of the 
National Health Service budget was directly related to obesity (O'Neill, 2010). In 
addition to health care costs, some believe that the severe obese lose a month of 
productivity for every year compared to normal weight individuals (Finkelstein et al., 
2010). Because of the social, economic, and health consequences of obesity, it is not 
surprising that many organizations are starting to make curbing obesity a top priority. 
Many government programs have been put in place to fight this pandemic. 
New laws even limit the food intake of individuals. These include modifying public 
school lunch programs so that children are consuming fewer calories (Department of 
Agriculture 2012). The programs also try to protect adults as seen in New York 
City's law to limit the size of soft drinks being sold (Grynbaum, 2012). 
These government programs have been designed to reduce food intake and 
increase energy expenditure to curb obesity. In some cases however, changing diet 
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and exercise is not enough, which means a third factor is involved in the obesity 
pandemic. This third factor is related to physiology in which genetics can play a role 
in making individuals more susceptible to obesity. 
One of the more well-studied physiological systems is the leptin system. 
Leptin is a hormone secreted by adipose tissue when fat storage is high and secreted 
less when fat storage is low. The hormone acts on the hypothalamus where it 
produces signals to reduce food intake and hunger and to increase energy 
expenditure. The leptin system helps maintain the lipostatic set point for weight 
regulation. Alterations in this system can lead to obesity. Mutations that prevent 
leptin hormone production or mutations that remove or alter the leptin receptor, can 
prevent individuals from feeling full and thus lead to obesity (Houseknecht, 1998). 
The leptin receptor is just one type of many G protein-coupled receptors (GPCRs) 
that have been discovered. 
G Protein-coupled Receptors 
Since Robert Lefkowitz pioneered the G protein-coupled receptor field in the 1970' s, 
hundreds of GPCRs have been discovered. GPCRs are responsible for several 
physiological functions as they respond to diverse stimuli such as hormones, 
neurotransmitters, pheromones, light, and odor (Ferguson, 2001). GPCRs have 7 
transmembrane domains at the plasma membrane with an intracellular C-terminus 
and an extracellular N-terminus end. Spanning the plasma membrane allows GPCRs 
to convert extracellular signals to intracellular signals through a process called signal 
transduction. 
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The structure of GPCRs is highly related to their function. All GPCRs have 
agonist binding domains that are very specific for a limited number of agonists. The 
location of these domains differ based on the type of agonist. Smaller ligands can 
bind to the receptor in the hydrophobic regions created by the transmembrane 
domains. Larger ligands bind to the extracellular regions of the transmembrane 
domains and to the N-terminus. They also have specific intracellular domains which 
allow the attachment of G proteins and subsequent signaling (Ferguson, 2001 ). 
GPCR Activation and Signaling 
Over a thousand GPCRs have been discovered and all rely on heterotrimeric G 
proteins to relay the extracellular signals they receive into intracellular messages. 
There are many different types of G proteins but they can be grouped into 5 more 
common groups; Gs, Gi, Gq, G12, and G13 . While some GPCRs will interact with only 
one type of G protein it is also common for a single GPCR to interact with many G 
proteins which will relay different intracellular signals (Ferguson, 2001). 
Heterotrimeric G proteins consist of three subunits; a, ~' and y. Gp and Gy are 
essentially always bound to each other and can only be separated by denaturation 
(Figure 1). Gais bound to the other subunits when it is also bound to GDP. Some Ga 
and Gp have sites of lipid modification which suggest they can interact with the 
plasma membrane. When GDP is exchanged for GTP on the Ga subunit, Ga loses 
affinity for and dissociates from Gp and Gy. This exchange process is assisted by 
GPCRs. When a ligand binds to a GPCR, conformational changes in the intracellular 
loops encourage heterotrimeric G protein binding. The bound Ga releases its GDP for 
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G Protein-coupled Receptor 
Signaling 
Phosphatases Downstream 
Signaling 
Figure 1: Diagram showing the major signaling steps of GPCRs. 
Agonist binding to the receptor causes GTP to be added to Ga 
which causes the separation of it from G~y. Ga and G~y both 
activate downstream signaling pathways until phosphatases 
convert the GTP to GDP on Ga. The G protein subunits then 
bind back together which ends their signaling. 
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GTP and the subunits dissociate. Ga is then able to conduct its intracellular signaling. 
Generally, Gas activates adenylyl cyclase, Gai inhibits adenylyl cyclase, Gaq activates 
phospholipase C, and Ga12 and Ga13 activate Rho (Buhl, 1995). Gpy also contribute to 
intracellular signaling when they are not bound to Ga (Clapham, 1993). 
GPCR Desensitization and Resensitization 
Activation of GPCRs by specific stimuli sets forth both signal transduction pathways 
and a process to remove the current signal and to prevent overstimulation. The 
process of preventing overstimulation is known as desensitization. In order for the 
cell to respond to a signal properly, it must receive and act on that signal for only a 
limited amount of time. Without the ability to prevent overstimulation, one signal 
could unnecessary activate the cell for an extended period of time. For this reason, 
desensitization plays an enormous role in maintaining normal physiology because 
many conditions can result from poor receptor desensitization (Hoyer, 2004). 
Over the years, more and more factors involved in GPCR desensitization have 
been discovered but it is unlikely that the entire process has already been described. 
The process of GPCR desensitization varies greatly from receptor to receptor but it 
generally includes uncoupling of the heterotrimeric G proteins due to receptor 
phosphorylation and arrestin binding, the internalization of the receptor to into 
endosomes, and occasionally a downregulation of the receptor by reducing its mRNA 
and degradation of existing receptors by lysosomes. The kinetics and magnitude of 
desensitization varies among receptors. Some range from just seconds to desensitize 
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completely to stimuli while for other receptors it is simply more difficult to activate 
the receptor during this period (Ferguson, 2001). 
Receptor Phosphorylation 
The first step in GPCR desensitization is generally covalent modification in the form 
of phosphorylation. This process is performed by two families of kinases, second 
messenger-dependent protein kinases and G-protein coupled receptor kinases (GRKs) 
(Lefkowitz, 1993). The second messenger-dependent protein kinases include 
downstream kinases such as cAMP-dependent protein kinases (PKA) and protein 
kinase C (PKC). These kinases do not discriminate between activated and inactivated 
receptors so they will phosphorylate both types of receptors (Lohse, 1990). GRKs on 
the other hand, will only phosphorylate agonist-activated receptors. Phosphorylation 
of activated receptors promotes the binding of arrestins which sterically prevent the 
binding of more heterotrimeric G proteins (Lohse, 1990, Ferguson, 2001 ). 
G protein-coupled Receptor Kinases 
All GRKs contain 4 similar domains, a catalytic domain to perform receptor 
phosphorylation, an amino-terminal domain believed to be related to substrate 
recognition, an Regulator of G-protein signaling (RGS) binding domain, and a 
carboxyl-terminal domain which helps concentrate GRKs to the plasma membrane. 
Phosphorylation of receptors by these kinases occurs at both serine and threonine 
amino acids at either the carboxyl-terminal tail domains or the third intracellular loop 
(Ferguson, 2001). There are currently seven known types of GRKs and each slightly 
varies in regards to the receptors they phosphorylate and how they are activated 
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(Premont, 1995). While GRKs often phosphorylate many sites, it is thought that only 
the first phosphorylation is necessary for receptor desensitization (Ohguro, 1993). 
Kong et al. investigated the role of GRK2 in the desensitization of the ~-
adrenergic receptor by creating a GRK2-K220L mutant that acted as a dominant 
negative for GRK2. This mutant lacks the kinase activity of wild type GRK2. 
Overexpression of GRK2-K220L creates a double mutant because it competes with 
GRK2. A 10 fold increase in the mutant compared to the wildtype takes away 90% 
of GRK2' s normal function (Kong, 1994). 
Jimenez-Sainz et al. has also found a role of GRK2 in shutting down the ERK 
pathway. The ERK pathway is a popular pathway activated by MCHRl and it was 
used as an indicator of receptor activation in this study. Overexpression of GRK2 
decreased the amount of ERK phosphorylation while GRK2-K220L caused an 
increase in ERK phosphorylation. If the GRK2 binding domains to Gu and G~y are 
malfunctioned, GRK2 fails to inhibit ERK activation. This suggests that GRK2 is 
activated downstream of G protein signaling to inactivate the ERK pathway. GRK2 
co localizes with MEK which is the author's hypothesis as to where this interaction 
with the downstream signaling pathway is taking place (Jimenez-Sainz et al., 2006). 
Fu et al. found similar effects of GRK2 because GRK2-K220L caused an increase in 
ERK pathway activation. This was alarming because the GRK2 dominant negative 
was seen as a potential treatment for heart failure but is causing concerns if it also 
increases the rate of tumors by increasing the growth promoting ERK pathway (Fu, 
2013). 
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Arrestins 
Full receptor desensitization generally requires more than initial phosphorylation. It 
often requires the binding of an "arresting agent" known as arrestins. The binding of 
arrestins to receptors both sterically prevents future binding of heterotrimeric G 
proteins and usually targets the receptor for endocytosis. Thus the binding of 
arrestins are extremely important to two of the three components of receptor 
desensitization; separation of the receptor from heterotrimeric G proteins and 
internalization. Arrestins bind very specifically to the GRK-phosphorylated sites 
rather than the phosphorylation sites of second messenger receptor kinases which 
shows that GRK phosphorylation of the receptor may be more important than the 
phosphorylation of second messenger kinases (Ferguson, 2001). 
Internalization 
The vast majority of GPCRs use internalization as a way to prevent the receptor from 
encountering more agonist and to remove the ligand that is already bound to the 
receptor. Although some GPCRs, such as the D3 dopamine receptor, have shown 
limited internalization following activation (Kuzhikandathil, 2004). Much of what is 
known from GPCR internalization was learned through research involving the P-
adrenergic receptor (PAR). While PAR endocytosis has been carefully documented, 
the exact pathway may not be the same for all GPCRs because the kinetics of various 
receptor internalization differs greatly from receptor to receptor (Ferguson, 2001). 
Initially phosphorylation of GPCRs was not considered to be important for 
internalization, but mutations of sites where GRKs generally act on caused a 
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decreased level of m2 AChR internalization (Moro, 1993). In addition, GRK2 
overexpression promotes some GPCR internalization. It is now accepted that that 
GRKs play an important role in GPCR internalization through receptor 
phosphorylation but it is not always required for all GPCRs such as the ~AR 
(Hausdorff et al., 1989). GPCR phosphorylation promotes the binding of ~-arrestins 
which as mentioned earlier both uncouple the receptor from heterotrimeric G proteins 
and promote internalization. Arrestins target GPCRs for clathrin-coated vesicle 
mediated internalization through the use of AP-2 heterotetrameric adaptor complex. 
Arrestins themselves also have clathrin-binding domains which stabilize the receptor 
in these areas. The clathrin-coated pits cause the internalization of GPCRs. 
Internalized GPCRs concentrate in vesicles where they are either recycled back to the 
plasma membrane or degraded by lysosomes. 
While internalization is a process of most GPCRs, the actual desensitization of 
the receptor occurs well before internalization which lessens its importance to 
desensitization. In addition, blocking GPCR internalization does not change its 
desensitization profile. However, internalization does seem to have an important role 
in GPCR resensitization (Ferguson, 2001). 
Resensitization 
Just as GPCR desensitization is important to prevent overstimulation, resensitization 
is important to prevent irreversible desensitization. Receptors need to be allowed to 
signal properly again after they have gone through desensitization to maintain 
homeostasis. Internalized GPCRs are located in endosomes where they are exposed 
12 
to GPCR-specific phosphatases which dephosphorylate the receptor. ~-arrestins seem 
to be excluded from the endosomes which allows the dephosphorylation of GPCRs (J. 
Zhang 1999). These receptors then follow one of two fates of resensitization; 
recycling to the plasma membrane or degradation followed by newly transcribed 
receptor. 
This process varies among GPCRs but at the very least takes several minutes 
(Ferguson, 2001). The process of internalization seems to be necessary for the GPCR 
dephosphorylation step because internalization-defective mutant GPCRs do 
desensitize but cannot resensitize (Barak et al., 1994 ). This solidifies the role of 
internalization for resensitization of GPCRs. 
MCH 
Melanin-concentrating hormone (MCH) in mammals is a 19 amino acid cyclic 
peptide. MCH was originally isolated from teleost fish where it played a role in skin 
color (Kawauchi, 1983). In mammals MCH plays a part in a variety of roles. It has 
been documented to play a role in appetite and energy expenditure (Shimada, 1998), 
resistance to hepatosteatosis despite fat-emiched diets (Wang, 2010), and resistance 
to aging-associated insulin resistance (Jeon et al., 2006). It is produced in the lateral 
hypothalamus (Bittencourt et al., 1992). It binds to two known GPCRs, MCHRl and 
MCHR2. Many animals, such as humans, have both GPCRs but rodents, which are 
often used in MCH research only express MCHRl (Tan et al., 2002). 
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MCHRl 
Melanin-concentrating hormone receptor 1 (MCHRl) is a GPCR that binds MCH and 
plays a role in energy expenditure and appetite. MCHRl signals through Gi, Go, and 
Gq depending on cell type which indicates that the ERK pathway is significantly 
activated following MCHRl activation (Saito 1999). MCHRl is fairly widely 
expressed in the body but predominantly within the brain (Takahashi 1995). In the 
brain specifically, MCHRl is expressed in areas related to motivation, feeding, and 
energy homeostasis. MCHRl is also expressed in adipose tissue where is helps to 
regulate leptin release (Bradley 2000). 
ERK Pathway 
The ERK pathway is a signaling pathway that has been shown to influence growth 
and differentiation of cells. The ERK signaling pathway is a cascade of several 
molecules that essentially activate one another in a specific order. Research is still 
being conducted on this pathway but much of the pathway has been well 
characterized. The order of cascade events was discovered by following 
phosphorylation from the plasma membrane to transcription factors and in reverse 
(Seger, 1995). The ERK pathway can be activated by a number of means but it seems 
all activation eventually converges to activate Ras. Ras-GTP can then recruit Raf 
which is consequently phosphorylated. Activated Raf then phosphorlyates MEK 
proteins. MEKs phosphorylate and activate ERKs. P-ERKs can be distinguished 
from inactivated ERKs through the use of antibodies. Activated ERKs can enter the 
nucleus where they can phosphorylate a number of transcription factors which results 
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in alteration of gene expression. Activation of the ERK pathway can result in a wide 
variety of cellular functions including cell proliferation and apoptosis (Kolch, 2000). 
MCHRl and Obesity 
One important study linking MCHRl and obesity was conducted by Marsh et al. 
(Marsh et al., 2002). It was previously shown that fasting mice developed increased 
levels of MCH mRNA which suggests that MCH and MCHRl function is related to 
appetite. Marsh et al. generated MCHRI-/- mice and found no pathological 
abnormalities or infertility. The body weights of normal and MCHRl-/- were also 
similar but the differences lay in fat mass. Both genders of MCHRl-/- mice have 
50% less fat and 7% more lean mass than wild type mice. The most significant data 
was MCHRl-/- mice response to high fat diets. The body weight of wild type mice 
increases substantially when fed a high fat diet instead of the regular chow. However, 
MCHRl-/- mice did not display an increase in body fat when they were fed a high fat 
diet. This suggests that MCHRl knockout mice are resistant to diet-induced obesity. 
The authors suggest that this resistance is a result of increased activity and subsequent 
energy expenditure (Marsh et al., 2002). 
The claim that MCH decreases energy expenditure and increases appetite has 
recently been disputed by a study. Imbemon et al. has injected Sprague-dawley rats 
with MCH and observed a similar increase in body weight and fat mass that has 
previously been observed. However, their reasoning for the change is drastically 
different than what has previously been reported. lmbemon et al. shows that MCH 
signaling in the lateral hypothalamus causes a change in liver and adipocyte cell 
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function. In the liver, MCH signaling causes the cells to retain more lipids. While in 
adipocytes, MCH signaling causes the fat cells to store more lipids. Together, these 
changes in cell function show how MCH signaling can increase the fat mass of an 
individual. While the MCH system is no longer expected to affect the appetite or 
metabolism of an individual as a result of peripheral signaling, it is still a therapeutic 
target because of its ability to increase fat mass through signaling in the 
hypothalamus (Imbernon et al. , 2013). 
Specific Aims 
The specific aims of this study focused on the desensitization and resensitization of 
MCHRl , observed through the ERK pathway. The first aim was to verify that the 
ERK pathway desensitizes to MCH. We then wanted to characterize how long this 
desensitization period lasted. We expected it to be around 30 minutes because that 
has been observed with other GPCRs (Mundell, 2008). Our third aim was to 
determine if internalization and degradation of MCHRl or another mechanism could 
explain the desensitization. And our final aim was to observe ERK pathway 
desensitization to other stimuli. This study is significant both to the field of GPCRs 
and to obesity. Characterizing alternative mechanisms of GPCR desensitization is 
important in studying other GPCRs. Also, determining a mechanism ofMCHRl 
desensitization will reveal potential therapeutic targets to fight obesity. 
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Materials and Methods 
Tissue Culture 
BHK-570 cells (ATCC) were cultured in DMEM- media (CellGro) with 10% fetal 
bovine serum (Atlanta Biological) and 1 % antibiotic antimycotic solution (Sigma Cell 
Culture). 3T3-Ll preadipocytes (ATCC) were cultured in DMEM- with 5% bovine 
calf serum (Atlanta Biological) and 1 % antibiotic antimycotic solution. Cultured 
cells were fed every three days and BHK 570 cells were split when they were 
confluent and the 3T3-Ll cells were split at 75% confluency. All cultured cells were 
kept in an incubator at 37°C, 5% CO2, and 80% humidity. 
Transfection 
Transfections were performed when BHK-570 cells reached 75% confluency and 
50% confluency for 3T3-Ll cells. Transfections used LipoD293 reagent from 
SignaGen following their recommended protocols. Transfection time ranged from 4 
to 24 hours depending on the experiment. Experiments were run approximately 48 
hours after the start of the transfection. Depending on the experiment, cultured cells 
were transfected with plasmids containing MCHRl, VSVg-MCHRl, PCDNA3, 
GRK2, GRK3, and GRK2-K220L (GRK plasmids courtesy of JeffBenovic's lab). 
Cell Based ELISA 
BHK-570 cells were seeded into 24-well plated and transfected with 2.5 µL 1 mg/ml 
each ofMCHRl-VSVg ± GRK2-K220L or± GRK3 or ±GRK5. Forty-eight hours 
post-transfection, culture media was aspirated and labeling buffer (0.02M HEPES and 
5% goat serum (MP Biomedicals) in DMEM-) with 1:1000 mouse a VSVg (Sigma) 
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was added for 2 hours at room temperature. The wells were washed twice with 
labeling buffer before 100 nM rat MCH (American Peptide) treatments for 0, 15, and 
30 minutes time points. The media was aspirated and the wells were washed with ice 
cold phosphate buffered saline (PBS) (140 mM NaCl, 2.5 mM KCl, 10 mM 
Na2HP04, 2 mM KH2P04, and pH to 7.4 in deionized water). Cells were fixed with 
3% paraformaldehyde in PBS for 20 minutes at room temperature. The wells were 
then washed three times with PBS before the addition of 1 :5000 goat a-mouse HRP-
conjugated secondary antibody (Bio-Rad) with 5% goat serum in PBS for 45 minutes. 
The wells were washed three times with PBS before the addition of 175 µL soluble 
POD blue (Roche) for 15 minutes on an orbital shaker. The reaction was stopped 
using 175 µL 10% sulfuric acid for 2 minutes. To a 96 well plate, 150 µL of each 
well was transferred and the absorbance was read at 450 run using a Synergy Hl plate 
reader (Bio Tek). 
Multiple MCH Treatments for ERK Signaling 
Cells were serum starved in DMEM- 2-12 hours prior to MCH treatments. Select 
dishes of cells were pretreated with 100 nM MCH for 10-15 minutes by carefully 
removing the media to limit agitation of the cells. All dishes were washed three times 
with DMEM- and the cells were incubated for 30 minutes before cells were treated 
with 100 nM MCH between O and 30 minutes. This procedure created two types of 
cells, ones that were treated twice with MCH and ones that were treated just once 
withMCH. 
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ERK Signaling Cell Lysate Harvesting 
Following the MCH treatments, dishes of cells were placed on ice and the media was 
aspirated. One hundred and fifty microliters of 2x sample buffer ( 4% SDS, 20% 
Glycerol, 0.12M Tris pH 6.8, and 10% 2-Mercaptoethanol) was added to each dish 
and the cells were scraped off of the dish into solution. Cell lysates were frozen prior 
to SDS-PAGE. 
MCHRl Cell Lysate Harvesting 
A lysing procedure developed by Danielle Feligno was slightly modified for 
effectiveness. The culture media was removed from the dishes and 1 mL of trypsin 
(HyClone) was added. Cells were scraped into a conical with lmL cold DMEM-. 
The conical was centrifuged for 20 minutes at 1,000 rpm at 4°C using an International 
Clinical Centrifuge. The supernatant was removed and the cells were washed in ice-
cold PBS. The conical was centrifuged again for 20 minutes at 1,000 rpm at 4°C. 
The supernatant was removed and the cells were resuspended in a lysing buffer 
containing 15 mM NaCl, 35 mM HEPES pH 7.4, 12 mM sodium deoxycholate, 35 
mM SDS, and 100 mM DTT in distilled water. The samples were rocked for one 
hour at 4°C. The samples were then boiled for 5 minutes and centrifuged for 20 
minutes at 13,000 rpm in a microcentrifuge. The lysates were kept at -20°C prior to 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). 
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
Cell lysates in 2x sample buffer were boiled for 5 minutes and centrifuged for 5 
minutes at 13,000 rpm before being loaded onto a 12% Bis-acrylamide-Tris SDS gel 
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using EZ-Run protein ladder (Fisher) as a molecular weight standard. Gels were run 
at 120 volts with Ix Running Buffer (25 mM tris-base, 220 mM glycine, and 3.5 mM 
SDS in deionized water) for about an hour or until the sample buffer reaches the 
bottom of the plates. 
Semi-dry Transfer 
The gel was soaked in Towbins solution (40 mM Tris-base, 35 mM glycine, 1 mM 
SDS, and 16% methanol in water) while on a nitrocellulose membrane (GE or 
BioRad) surrounded by blot paper for 10 minutes. The contents were transferred at 
15V for 30 minutes using a semi-dry transfer apparatus (BioRad). 
Wet Transfer 
A wet transfer method (BioRad) was also used to transfer gel contents onto a 
nitrocellulose membrane. The following contents were soaked in transfer buffer (25 
mM Tris, 192 mM glycine, 20% v/v methanol, pH 8.3); grey side of cassette, fiber 
pad, filter paper, gel, nitrocellulose membrane, filter paper, and fiber pad for 15 
minutes. The transfer apparatus (Mini Trans-Blot® Electrophoretic Transfer Cell) 
was set up according to BioRad instruction and the transfer was run at 350 mA for 
one hour. 
Western Blot 
Following transfer, the nitrocellulose membrane was then blocked in 5% non-fat dry 
powdered milk (Great Value) in TBS-T (50 mM Tris, 150 mM NaCl, and 0.05% 
Tween 20 in deionized water pH 7.6) for 1 hour at room temperature on an orbital 
shaker. Primary antibody was added at 1: 1000, in 5% milk in TBS-T overnight at 
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4°C on an orbital shaker. Various primaries were used: goat a-MCHRl (Santa Cruz 
Biotechnology), rabbit a-MCHRl (Santa Cruz Biotechnology), rabbit a VSV g 
(Sigma), rabbit a-Total ERK (Cell Signaling), and mouse a-Phosphorylated ERK 
(Cell Signaling). The nitrocellulose paper was washed with TBS-T three times for 10 
minutes before the addition of secondary antibody at 1 :5000 in 5% milk in TBS-T. 
Various HRP conjugate secondaries were used: goat a mouse (BioRad) and goat a 
rabbit (BioRad). Secondary antibody was added for 45 minutes at room temperature 
on an orbital shaker. The blot was washed three times for 5 minutes with TBS-T. 
Western Lightning Plus enhanced chemiluminescence substrate (PerkinElmer) was 
added to the blot according to its instructions and the luminescence was observed 
using film (Kodak). 
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Results 
Obesity is both an international and domestic pandemic and the problem is only 
growing. Easy access to food, especially high caloric foods, has combined with 
general lack of physically labor to affect a larger portion of adults (Pi-Sunyer, 2002). 
There are nearly 500 million adults worldwide that are currently obese and that 
number is only expected to grow (Kral, 2012). Obesity has severe financial and 
health consequences which include diabetes and heart disease (Pi-Sunyer, 2002). 
Individuals are mostly limited to dietary changes and exercise to fight their conditions 
but there is hope therapeutic drugs can also contribute to fighting obesity. 
The melanin-concentrating hormone (MCH) has been of interest to fight 
obesity because of its expected relation to appetite and energy expenditure. Recently, 
the physiological role of MCH has been shifted from appetite and energy expenditure 
to lipid accumulation in the periphery. MCH triggers lipid accumulation and uptake 
in the liver while it stimulated lipid storage in adipocytes (Imbernon et al., 2013). 
This combined effect of MCH will increase the fat storage in an individual which 
make the MCH system a potential therapeutic target to fight obesity. 
MCH is produced and acts upon the lateral hypothalamus in mammals. The 
hormone binds to two homolog GPCRs, MCHRl and MCHR2. Previously, Marsh et 
al. has shown that MCHRl knockout mice are less susceptible to diet induced obesity 
because they were leaner than wild-type mice. Marsh et al. attributed the reduction in 
obesity to an increase in energy expenditure and decrease in appetite but Imbernon et 
al. has recently countered these claims (Imbernon et al., 2013). Imbernon et al. has 
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shown that mice receiving injections ofMCH are more obese than mice that do not 
receive the treatment and this is consistent with prior studies. They have also shown 
however, that the change in weight is not solely related to appetite or energy 
expenditure but because of changes in the periphery. MCH signaling increases lipid 
accumulation by the liver which increases the amount oflipids within the body. 
MCH signaling also increases lipid storage in adipocytes which increases the fat mass 
of an individual. MCH signaling increases fat mass by altering the fat storage of 
individuals (Imbernon et al., 2013). Although the perceived physiological 
mechanism behind MCH has changed, the system is still a potential therapeutic 
target. 
Activation ofMCHRl signals through Gs, Gq, and Gi proteins. These three 
pathways eventually converge on the ERK pathway which is why ERK 
phosphorylation was chosen as the readout of MCHRl activation. This study focused 
on characterizing the desensitization and resensitization of MCHRl. Most GPCRs 
desensitize by internalizing the receptor into the cytosol from the plasma membrane. 
Saito et al. claims that this is the mode of desensitization of MCHRl as 40-50% of 
the receptor is internalizes following 30 minutes of MCH treatment (Saito et al., 
1999). Aside from this paper, there is little other evidence to determine the exact 
mode of desensitization. 
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MCHRl Stimulation leads to Activation of the ERK Pathway 
In order to measure the activation ofMCHRl , stimulation of the ERK pathway was 
observed using a Western Blot. BHK-570 cells were transfected with MCHRl and 
48 hours later, these cells were treated with lOOnM MCH for 0-30 
minutes. Detection of both total and phosphorylated ERK using western 
hybridization was used as the indicator of MCHRl activation which is characterized 
by the phosphorylation of ERK. The blot showed that phosphorylation of ERK was a 
sufficient indicator of MCHRl activation because it was time dependent and ERK 
was not activated in treated cells lacking MCHRl (Figure 2A, Baseline lanes). This 
experiment suggests that ERK is an appropriate readout of MCHRl activation so it 
was observed in subsequent experiments. 
MCHRl Signaling Desensitizes the ERK Pathway 
After determining that the ERK pathway is efficient in observing MCHRl activation, 
the next goal was to use it to observe any pathway desensitization. Receptor 
desensitization is extremely important to their basic function. From a physiological 
standpoint, an organism does not want one signal to be on forever because it may not 
always be necessary for survival. To prevent signal overstimulation, receptors 
desensitize their pathways to the stimulus so that signals can generally be turned on 
and off in a short period of time. 
In order to measure the activation and subsequent desensitization of MCHRl , 
activation of the ERK pathway was observed using a Western Blot (Figure 2A). In 
the initial experiments, BHK-570 cells were transfected with MCHRl and these cells 
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Figure 2: A) Western blot, cells were only treated once with 100 nM 
MCH (baseline) or cells were treated with MCH for the given time after 
an initial 15' treatment followed by a 30' washout DMEM- (Multiple 
Treatments). Desensitization is shown as ERK cannot be 
phosphorylated again after only a 30' washout. B) Densitometry of the 
western using ImageJ normalizing the activated ERK to the total ERK. 
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were treated with 1 OOnM MCH approximately 48 hours later. After an initial 15 
minute MCH treatment to half of the dishes, all of the dishes were washed 3 times 
with DMEM-. Following 30 minute incubation, dishes were treated again with MCH 
for various time points. A Western Blot using both total and phosphorylated ERK 
was used as the indicator of MCHRl activation which is characterized by the 
phosphorylation of ERK. The Western Blot in Figure 2AB shows 7 fold ERK 
activation of BHK-570 cells with MCHRl treated only once with MCH for 10 
minutes. However, when cells were pretreated with MCH, there is very limited 
activation of ERK following the 30 minute incubation and second MCH treatment. 
The amount of total ERK observed in the Western Blot was used to normalize the cell 
number in the creation of the densitometry of this blot (Figure 28). This implies that 
the ERK pathway significantly desensitizes to MCH for at least 30 minutes. 
A concern following this experiment is that transfected BHK-570 cells are a 
nonendogenous model utilizing a cell line that does not naturally express MCHRl. 
Since nonendogenous models may react differently, it is important to observe any 
MCHRl desensitization in an endogenous cell line. 3T3-Ll mouse preadipocytes, 
which naturally express MCHRl , were used in a very similar experiment as Figure 2. 
While the treatment and lysate harvesting was identical as before, one major change 
was that the pretreatment of MCH was changed to 10 minutes instead of 15 for all 
future experiments. This change was made because Figure 2 showed maximum ERK 
activation after 10 minutes with MCH so this was chose for the length of the 
pretreatment. Figure 3 shows the Western Blot of the 3T3-Ll MCH treatments. It 
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Figure 3: Western blot, 3t3-Ll cells were only treated once with 100 
nM MCH (Baseline) or cells were treated with MCH for the given 
time after an initial 1 O' treatment followed by a 30' washout (Multiple 
Treatments). Desensitization is shown as ERK cannot be 
phosphorylated again after only a 30' washout. 
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shows ERK activation when cells were treated once with MCH but a reduced ERK 
activation following the second MCH treatment. The amount of total ERK for each 
dish is consistent which means that a difference in cell number did not account for the 
variation in ERK activation. These results are very similar to the nonendogenous 
model observed in Figure 2 which suggests that using transfected BHK-570 cells with 
MCHRl for future experiments is an appropriate cell model. 
Resensitization of the ERK Pathway to MCH takes over 70 Minutes 
Equally as important as characterizing the desensitization of a receptor is 
characterizing its resensitization. Determining the length of time that a receptor 
desensitizes is significant because it sheds light onto the physiology of the hormone. 
Figures 2 and 3 show that the ERK pathway significantly desensitizes to MCH for at 
least 30 minutes. The next logical aim is to determine exactly how long MCHRl 
mediated ERK pathway desensitization lasts. 
In order to determine how long MCHRI resensitization takes, a Western Blot 
was used again to observe the phosphorylation of ERK following MCH treatments. 
BHK-570 cells transfected with MCHRI were pretreated with IOOnM MCH. Unlike 
in the previous experiments where the incubation period between the two MCH 
treatments was kept constant, that period is varied in this experiment. By varying the 
time between MCH treatments and observing ERK activation in a Western Blot, we 
can determine the length of time needed for the ERK pathway to resensitize to MCH. 
Figure 4A shows the Western Blot with both total and phosphorylated ERK. The 
ERK activation in cells treated once with MCH for 10 minutes is used as the level to 
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determine that ERK is fully resensitized to MCH. The densitometry in Figure 4B 
shows that ERK activation does not return back to normal for over 70 minutes. This 
implies that the ERK pathway desensitizes to MCH for over 70 minutes. 
Protein Levels of MCHRl Increase following MCH Treatment 
Receptor desensitization is necessary to prevent overstimulation of a cell. There are 
several potential methods of desensitization that have been observed for GPCRs. The 
most common method of desensitization of GPCRs is receptor internalization which 
can be followed by degradation of the receptor. 
To test the hypothesis that MCHRI is degraded following activation, MCHRI 
protein levels were observed using a Western Blot following long term MCH 
treatments. BHK-S70 cells were transfected with MCHRI-VSVg and were treated 
with 1 OOnM MCH for up 24 hours. All of the MCH treatments were lysed at the 
same time to ensure that all of the cells had equal transfection and time with the 
receptor plasmid. The Western Blot in Figure SA shows MCHRl-VSVg protein 
levels. Figure SB shows the densitometry of each banding shown in the Western Blot 
and its relative molecular weight. These figures show an approximate two fold 
increase in receptor protein levels following an 18 hour MCH treatment which 
suggests that MCHRI is not degraded following MCH treatment. 
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Figure 5: A) Western blot to determine ifMCHRl protein levels 
decrease following long-term MCH treatment. BHK cells were 
transfected with VSV-g tagged MCHRl or pcDNA3 empty plasmid as a 
negative control. After 24 hours, these cells were then treated with 
lOOnM MCH as noted. The PCDNA3 lane is blank so the darkened 
areas in the other lanes are all MCHRl. Molecular weights of the bands 
were determined using the molecular weight standard. B) Densitometry 
was used to quantify the changes on the blot using ImageJ. 
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MCHRl is not Removed from the Plasma Membrane in High Quantities 
Internalization is very common for many GPCRs following hormone treatment. Saito 
et al. has already reported that 40-50% of MCHRl is internalized following 30 
minutes of MCH treatment (Saito et al., 1999). Thus it was a hypothesis that even if 
MCHRl does not degrade following MCH treatment, it may still internalize to 
prevent overstimulation of the cell. 
To observe internalization of MCHRl, a modified cell-based ELISA was 
performed. BHK-570 cells cotransfected with VSVg-MCHRl and either GRK 2 DIN 
or± GRK3 or ±GRK5. GRKs have been shown to help increase GPCR 
internalization by phosphorylating the receptors. The cell surface was coated with 
mouse a VSV g prior to 100 nM MCH treatment between O and 60 minutes. Cells 
were fixed and goat a-mouse HRP-conjugated secondary antibody with POD blue. 
The absorbance was measured which is directly related to the amount of VSV g-
MCHRl at the plasma membrane. 
Control cells that were not cotransfected with a GRK showed that -15% of 
VSVg-MCHRl internalized following 30 minutes of MCH treatment which is 
consistent with what was observed by Jay Moden (Moden, 2012). Internalization was 
not substantially increased with the cotransfection of GRK5 (Figure 6), or GRK3 
(Figure 7). Additionally, GRK2-K220L took away all VSVg-MCHRl internalization 
(Figure 7). This suggests that GRK2 is needed to provide any of the MCHRl 
internalization that is observed. GRK2 is often needed for GPCR internalization and 
it has been shown to colocalize with MCHRl (Kong et al., 1994, Eberle et al., 2004). 
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ELISA protocol. Control BHK-570 cells were transfected with just 
MCHRl while other BHKs were cotransfected with MCHRl and 
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Figure 7: Internalization ofMCHRl was measured using an ELISA 
protocol. Control BHK-570 cells were transfected with just MCHRl 
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GRK2 Plays a Role during MCHRl mediated ERK Desensitization 
Since limited internalization of MCHRI was observed, it was hypothesized that 
another mode of desensitization is responsible for the limited activation of ERK 
following repeated MCH treatments. Since this mode would have to occur while 
MCHRI is at the plasma membrane because only a limited amount ofMCHRl were 
internalized, we looked at factors that affect MCHRl at this location. Previous 
studies have shown that GRK2 is necessary for P2-adrenergic receptor desensitization 
which is a GPCR like MCHRI (Kong et al., 1994). We were drawn to GRK2 
because of the affinity it has shown for MCHRI and we hypothesized that 
phosphorylation of the receptor could block the binding of G proteins (Eberle et al., 
2004). GRKs are known to phosphorylate GPCRs. This phosphorylation step is one 
of the processes that leads to internalization of GPCRs. Blocking G proteins for an 
extended period of time could be the method ofMCHRl desensitization. 
It was first necessary to determine if MCH could still activate the ERK 
pathway if GRK2 is nonfunctional. To test this, BHK-570 cells were cotransfected 
with MCHRl and GRK2-K220L which is a GRK2 dominant negative and treated 
with lOOnM MCH. ERK activation was observed using a Western Blot. Figure 8 
shows that the ERK pathway is still activated by MCH in a similar way to 
what was seen in prior experiments even if GRK2 is not functional. This means that 
GRK2 is not necessary for proper activation of the ERK pathway by MCH. 
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Figure 8: Western blot; BHK-570 cells transiently-expressing 
MCHRI in pcDNA3 and GRK2 dominant negative were treated 
for 0-30 min with 100 nM MCH and harvested. The blot shows 
that the ERK pathway is still activated by MCH in the presence of 
a GRK2 dominant negative. 
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To test the hypothesis that GRK2 has a function in MCHRl mediated ERK 
pathway desensitization, ERK activation was observed using a Western Blot in cells 
without functional GRK2. BHK-570 cells were cotransfected with MCHRl and 
GRK2-K220L. This experiment followed a very similar protocol to the earlier 
desensitization experiments. These cells were pretreated with 1 OOnM MCH for 10 
minutes followed by 3 DMEM- washes. Following a 30 minute incubation period, 
the cells received a second MCH treatment for various time points. Following lysing, 
total ERK and phosphorylated ERK were detected using a Western Blot. When the 
blot in Figure 9 is compared to that in Figure 2A, it is clear that ERK activation is 
present even after the second treatment ofMCH. This suggests that GRK2 is 
necessary for MCHRl mediated ERK pathway desensitization. This isn't entirely a 
surprise because GRK2 has been shown to decrease ERK stimulation (Jimenez-Sainz 
et al. , 2006). However, the complete lack of ERK desensitization is a surprise. In the 
previous MCHRI mediated ERK desensitization experiments in Figure 2AB, 
functional GRK2 is present throughout the experiment and ERK is still stimulated, 
which suggests that GRK2 may take time to act upon ERK stimulation. 
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Figure 9: Western blot, BHK-570 cells cotransfected with MCHRI and 
GRK2 dominant negative were only treated once with MCH (Baseline) 
or cells were treated with 100 nM MCH for the given time after an 
initial 1 O' treatment followed by a 30' washout (Multiple Treatments). 
The blot shows that ERK is activated in both MCH treatments. 
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ERK Desensitization is Similar with other Activators of ERK 
A concern is that during this study, the ERK pathway could be desensitizing itself and 
that the type of stimulus is irrelevant to the resulting pathway desensitization. To test 
if the stimulus will affect the type of ERK desensitization that is observed, two other 
activators of ERK were tested; activation ofMCHR2 and isoproterenol treatment. 
MCHR2 is a homolog ofMCHRl which binds the same hormone and activates the 
same pathways (An et al., 2001). Isoproterenol, which is an agonist of ~-adronergic 
receptors, activates ERK by signaling through Gs and Gi proteins (Zou et al., 1999). 
To test if MCHR2 activation results in the desensitization of the ERK 
pathway, a Western Blot was used following MCH treatments. BHK-570 cells were 
transfected with MCHR2. Cell lysates were analyzed with a Western Blot following 
an MCH treatment protocol identical to the one in Figure 9. The Western Blot in 
Figure 1 OA shows ERK activation following a single and multiple MCH treatment for 
the indicated times. Figure 1 OB is the densitometry of the Western Blot which uses 
. the amount of total ERK to normalize for cell number. Figure 10 shows that ERK 
activation is decreased after the second MCH treatment which suggests that the ERK 
pathway is being desensitized when MCHR2 is activated in a similar manner to the 
desensitization of the ERK pathway following MCHRl activation. 
Next we wanted to test if the ERK pathway will desensitize in a similar 
manner when cells were treated with isoproterenol which is another stimulator of this 
pathway (Zou et al., 1999). BHK-570 cells were treated with isoproterenol in the 
same manner as the MCH treatments, with one group of cells receiving a single 
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treatment while another received multiple isoproterenol treatments. The activation of 
the ERK pathway was observed using a Western Blot which is shown in Figure 11. 
This figure shows that ERK is not activated after the second treatment with 
isoproterenol. This implies that the ERK pathway may be desensitizing in the same 
manner when treated with isoproterenol as with the activation of both MCHRl and 
MCHR2. This means that it is possible that the ERK pathway is desensitizing itself 
in the same way regardless of the type of stimulation. If this were the case, different 
activators of the pathway would result in similar ERK desensitization. 
The first aim was to observe MCH-mediated ERK desensitization which is 
shown in Figures 2 and 3. Resensitization of the ERK pathway to MCH took over 70 
minutes. After observing limited internalization ofMCHRl, it suggests that 
resensitization of the receptor occurs at the plasma membrane which is unlike most 
GPCRs which need internalization to resensitize. When Figures 2, 3, 10, and 11 are 
compared, they all show a similar desensitization of the ERK pathway which gives 
support to the argument that the observed desensitization is occurring at the pathway 
level rather than the receptor level. Figure 9 shows that GRK2 is needed for proper 
MCH-mediated ERK desensitization. While it was initially thought that 
phosphorylation of the receptor may induce desensitization, it is possible that GRK2 
acts on the ERK pathway to induce desensitization (references from earlier). Since 
only GPCRs were used to activate the ERK pathway, either scenario is possible 
because GRK2 could act upon the receptor or/in addition to the ERK pathway. 
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ERK Pathway Desensitization with 
Isoproterenol Treatment 
Baseline 
·.Multiple 
Treatments 
~irt1e {min) with 100 nM MCH 
PC O 5 20 30 Antibody: 
P-ERK 
Total ERK 
P-ERK 
Total ERK 
Figure 11: Western blot, BHK cells were only treated once with 10 
µM Isoproterenol or cells were treated with Isoproterenol for the 
given time after an initial 1 O' treatment followed by a 30' washout. 
Desensitization is shown as ERK cannot be phosphorylated again 
after only a 30' washout. Blot is easier to visualize on the film. 
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Discussion 
Obesity is a major issue worldwide in which nearly 500 million adults are obese (Kral 
et al., 2012). Previous studies have shown that mice lacking MCH and their 
significant pathways are less susceptible to diet-induced obesity (Marsh et al., 2002). 
This suggests that targeting MCH or MCHRl could result in an anti-obesity drug. 
For this reason, this study chose to focus on the natural desensitization of MCHRI. 
MCHRl signals through Gi, G0 , and Gq pathways (Chung, 2009). The ERK pathway 
is downstream of many G proteins which makes it a good choice to follow MCHRl 
activation. 
Verifying MCHRl-mediated ERK Desensitization 
To determine if the ERK pathway desensitizes to MCH, cultured BHK-570 and 3T3-
Ll preadipocytes were treated twice with 100 nM MCH with a washout period in 
between. The level of phosphorylated ERK was determined using a Western Blot 
which is a readout of MCHRl activation since MCH signaling leads to ERK pathway 
activation (Oh et al., 2010, Cook et al., 2008). We determined that in both cell types, 
the ERK pathway substantially desensitizes to MCH as there is no phosphorylation of 
ERK following the second hormone treatment 30 minutes following the first (Figures 
2 and 3). We also determined that maximal ERK stimulation occurs following 10 
minutes of MCH treatment. 
The results in these experiments compared well to literature. Our lab has 
previously determined that maximally ERK activation occurs following 10 minutes of 
MCH treatment (Cook 2008). ERK does not remain phosphorylated for an extended 
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period of time because signals cannot permanently stay on while maintaining proper 
physiology and homeostasis. The activation likely goes away due to phosphatases 
that deactivate the activated ERK molecules. 
A special aspect of this experiment that should be noted is that we chose to 
use a fairly high concentration ofMCH, 100 nM. The Kct ofMCH/MCHRl binding 
has been reported to be around 0.1 nM (Drozdz, 1995). In addition, the only reported 
serum MCH levels were highly debated and questioned (Gavrila et al. , 2005, Walters, 
2005). Therefore we do not know how our MCH concentration compares to that in 
vivo but we do know that because of the Kct we are flooding MCHRl with MCH. 
However, this was our intention. The goal of our MCH treatments was to activate as 
much MCHRl as we could at the same time. We did not want only half of the 
receptors to be activated in the first treatment because if desensitization occurs at the 
receptor level, half of the receptors are still allowed to activate following the second 
hormone treatment. If this were the case, we would probably not observe 
desensitization of the ERK pathway even though it was happening at the receptor 
level. Our proposed way around this problem was to flood MCHRl with MCH so 
that a high percentage of them bound to MCH after the first treatment. This gives us 
a better idea on if desensitization is occurring or not because we can be confident that 
most of the receptors were activated after the first MCH treatment. 
After observing desensitization of the ERK pathway to MCH, some possible 
mechanisms were hypothesized. Most GPCRs, like MCHRl, internalize the receptor 
into the cytosol where the agonist can be removed from the receptor. Occasionally, 
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GPCR phosphoryaltion leads to desensitization while the receptor is at the plasma 
membrane. D3 dopamine receptor desensitization is hypothesized to occur because 
of a conformational change in the receptor due to phosphorylation (Kuzhikandathil et 
al., 2004). GPCR phosphorylation could also prevent G protein binding which would 
prevent future signal transduction. Regulators of G protein signaling (RGS) have 
been shown to accelerate the dephosphorylation of activated Ga which decreases 
signaling (Hunt, 1996, Watson, 1996). Since expression of RGS increases following 
some agonist stimulation, increased activated RGS protein could be responsible for 
desensitization periods (P. Zhang et al., 2011). Another mechanistic explanation for 
the observed desensitization could be that the pathway desensitizes. Some of these 
possible mechanisms of MCHRl-mediated ERK desensitization were investigated 
later in this study. 
An alternative explanation for ERK desensitization in Figures 2 and 3 is that 
the hormone is not being washed off with the three serum-free washes. If MCH 
· remains bound to MCHRl , the receptors may not be reset to future signaling. To 
increase the chance that MCH was being washed off, we used a common acid/salt 
buffer to perform the wash instead of serum. However, this method created abnormal 
and inconsistent ERK activation, possibly because the acidic buffer agitated the 
cultured cells or altered receptor conformations which could result in the abnormal 
ERK signaling. 
Another way to measure the hormone still in serum following washes was to 
use fluorescent MCH. Rhodamine-MCH was added to cells and the level of 
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fluorescence was measured before and after three serum washes. A significant 
decrease in fluorescence would indicate the hormone is being washed off while 
consistent fluorescence would suggest it is not being washed off. Neither was the 
case as consistent fluorescent data was unable to be obtained potentially due to the 
sensitivity of our plate reader. Even if fluorescence was consistent, the different 
binding affinity ofMCH and Rhodamine-MCH would have to be determined. 
In any case, we are fairly confident that the serum washes did remove the 
majority of MCH from the first treatment. This confidence stems from the fact that 
changing the media three times should greatly reduce the free concentration of MCH 
in the serum. When serum MCH concentration is substantially lower that the 
MCH/MCHRI Kd ofO.l nM, bound MCH should be removed from MCHRI (Drozdz 
et al. , 1995). 
Another issue is that a nonendogenous cell model is used for the majority of 
our experiments. Transfecting a form of MCHRI into cells was easier to study with 
for a couple of reasons. Transfection resulted in a substantial amount of MCHRI 
which meant it was easier to observe ERK activation. Using VSV g-MCHRI was 
easier for some experiments because our antibodies for VSV g were much better. than 
those for M CHR I . We do not believe using a nonendogenous cell model is an issue 
because ERK activation and desensitization was observed to be similar in an 
endogenous model (Figure 3). Also, VSV g-MCHRI has been shown to signal 
similarly to normal MCHRI so for the experiments were it was used we don't think 
that should be a concern either (Cook 2008). 
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Another concern is that only the ERK pathway was observed to visualize 
MCHRl activation, desensitization, and resensitization. MCHRl activates a number 
of pathways in addition to ERK so the assumption cannot be made that what is 
happening to the ERK pathway following MCHRl activation is also occurring to the 
many other pathways activated by MCHRl. A future direction is to observe the other 
pathways activated by this receptor and compare their potential desensitization to that 
of the ERK pathway which could provide more clues as to how MCHRl 
desensitization is occurring. Another future direction of this portion of this study 
would be to verify that MCH is actually being washed off. 
The significance of observing MCHRl-mediated ERK desensitization is 
substantial. Better understanding of signaling desensitization following MCHRl 
activation could lead to new therapeutics that would treat of a variety of disorders. 
MCH signaling serves roles in many conditions including mood (Gehlert et al., 2009) 
and obesity (Segal-Lieberman et al., 2003). MCHRl antagonists have already been 
shown to limit weight gain in leptin-deficient mice (Segal-Lieberman et al., 2003). 
Characterization of ERK Resensitization to MCH 
The next aim in this study was to determine the length of time required for the ERK 
pathway to resensitize to MCH. BHK-570 cells transfected with MCHRl were 
treated twice with MCH with the incubation period in between treatments being 
varied in length. We wanted to determine the minimum amount of time required for 
ERK phosphorylation to return to the first MCH treatment level. A Western Blot 
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revealed that it takes at least 70 minutes for the ERK pathway to resensitize to MCH 
(Figure 4). 
Literature has seemed to neglect characterizing the exact length of 
desensitization of GPCRs. One study using P2Y1 and P2Y12 receptors showed that 
these GPCRs resensitized to agonist following 30 minutes of incubation (Mundell et 
al., 2008). This is slightly surprising because it takes MCHRl over twice as long to 
resensitize but not completely unexpected because they are different receptors and 
will behave differently. 
Resensitization of GPCRs typically requires dephosphorylation of the 
receptor. It was once believed that receptor endocytosis is required for the 
dephosphorylation step. The A2A adenosine receptor does not dephosphorylate or 
resensitize when internalization is blocked by an inhibitor (Mundell et al., 2008). 
However, not all GPCRs require receptor endocytosis for resensitization. Both IP-
prostanoid receptor and thryrotropin-releasing hormone receptor dephosphorylate and 
resensitize normally if internalization is blocked (Mundell et al., 2008, Jones, 2005). 
Since we observed very limited MCHRl internalization (Figures 6 and 7), it suggests 
that MCHRl does not require endocytosis to resensitize to stimulus. However, the 
dephosphorylation and resensitization of the receptor may be skewed or irrelevant if 
the observed desensitization occurs independent ofreceptor phosphorylation. For 
example, if the ERK pathway is desensitizing itself or by a component unrelated to 
the receptor, receptor phosphorylation and dephosphorylation may be irrelevant to 
resensitization for MCHRl and the ERK pathway. 
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MCHRl seems to desensitize the ERK pathway in such a way that the 
desensitization is 'all or nothing.' What this means is that the ERK signal does not 
not gradually comeback following the second MCH treatment, but rather remains at 
basal activation for 70 minutes until full activation comes back at the 80 minute 
interval. This suggests that the desensitization mode is definite and cannot be simply 
overcome by increasing the stimuli but this will need to be further tested to be 
confirmed. Additionally, the fact that ERK activation is either basal level or maximal 
level during the resensitization suggests that most of MCHRl is being bound by 
MCH at the same time. We used a higher concentration of MCH so that all of the 
receptors would become activated at the same time and Figure 4 suggests that this is 
indeed the case. 
In future MCHRl resensitization experiments, it would be necessary to 
compare the ERK pathway resensitization to that observed in the other pathways 
activated by MCHRl. It would also be interesting to see if an increased dosage of 
MCH for the second treatment could return ERK activation quicker than 70 minutes. 
This could indicate if the desensitization of the ERK pathway following MCH 
signaling is absolute or just more difficult to activate during the desensitized period. 
Observing the resensitization of the ERK pathway to MCH is significant 
because literature has shown a role for MCH and the ERK pathway in the 
hypothalamus. Pereira-de-Silva et al. has shown that MCH signaling results in ERK 
pathway desensitization in the hypothalamus (Pereira-da-Silva, 2005). Our 
experiment sheds some light to the time period that takes place during the 
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resensitization of the ERK pathway to MCH. Pereira-de-Silva et al. has shown 
evidence that MCH's most important role in the hypothalamus may not be activation 
of ERK but rather the subsequent desensitization of ERK following MCH signaling 
(Pereira-da-Silva et al., 2005). 
Determining the Mechanism of ERK Desensitization to MCH 
MCHRJ does not Degrade Following MCH Treatment 
VSVg-MCHRl protein levels were measured using a Western Blot following MCH 
treatment oftransfected BHK-570 cells for up to 24 hours (Figure 5). VSVg-MCHRl 
protein levels increased for 18 hours following a decrease after 24 hours of MCH 
treatment. The increase in MCHRl protein suggests that the receptor becomes more 
stable following MCH binding and not that more of it is transcribed because the 
promoter is not included in the transfected plasmid. The decrease in MCHRl protein 
after 24 hours is an anomaly because the VSV-g tagged MCHRl plasmid was present 
in every treatment time for the same amount of time. Therefore, the degradation of 
the plasmid is not a likely explanation. It is possible that these cells simply were not 
transfected well. Regardless, the increase in MCHRl protein following MCH 
treatment suggests that the receptor is not degraded following hormone treatment as is 
observed in some GPCRs. 
A special aspect of this experiment and in the later ELISA experiments is that 
VSV g tagged MCHRl was used rather than normal MCHRl. The reasoning behind 
this choice is that the antibody to VSV g works much better than the antibodies we 
had to MCHRl. Since our lab has previously shown that VSV g-MCHRl signals 
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through the ERK pathway in a similar manner to normal MCHRl, we still feel this 
experiment is relevant (Cook 2008). 
However, an alternate explanation for the results of this experiment could be 
that VSV g-MCHRl is simply more resistant to normal MCHRl to degradation. One 
way we tried to ease these concerns was to follow fluorescently labeled MCHRl to 
lysosomes. MCHRl-e YFP was used with LysoTracker to visualize any receptor 
trafficking and localization to lysosomes following MCH treatment. Unfortunately, 
this experiment was unsuccessful possibly do to insufficient labeling of the cultured 
cells. 
This experiment was significant because it suggests that degradation of 
MCHRl is not a likely reason for the observed ERK desensitization immediately 
following MCH signaling. This encouraged us to look at other desensitization 
mechanisms. One interesting aspect of this experiment is the suggestion that 
activated receptors are more stable. Increasing the stability of MCHRl suggests that 
upon an initial activation, a second round of hormone could increase the response 
from the first as long as they are resensitized to the hormone. A way to test this 
would be to treat cells with MCH and wait 12 hours before a second treatment and 
compare the activation of ERK to cells that were not pretreated with MCH. 
Limited MCHRI Internalization following MCH Treatment 
A modified cell-based ELISA was used to measure the rate ofVSVg-MCHRl 
internalization in BHK-570 cells following MCH treatment. To encourage 
internalization, GRKs 3 and 5 were cotransfected into the cultured cells. GRKs have 
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been shown to help increase GPCR internalization by phosphorylating the receptors. 
However, none of the GRKs were able to substantially increase MCHRI 
internalization and GRK2-K220L removed all MCHRI internalization (Figures 6 and 
7). 
About 15% of MCHRI internalized following 30 minutes of MCH treatment. 
GRK3 only partially increased MCHRl internalization to 35% following 60 minutes 
ofMCH treatment. MCHRI cotransfected with GRK2-K220L did not internalize at 
all following 60 minutes of MCH treatment. This suggests that MCHRI does not 
internalize well enough to account for the level of desensitization that is observed in 
the ERK pathway. 
A concern about this assay is that the antibody losing affinity for the receptors 
could be confused with internalization of the receptor. This is accounted for by 
comparing the fluorescence of the experimental cells to cells that were not treated 
with MCH and therefore should not be internalizing anyway. A way to ease this 
concern would be to measure MCHRl internalization in another manner. YFP-
MCHRl was transfected into cultured cells and the fluorescence was measured using 
a plate reader following MCH treatment. If internalization occurred, fluorescence 
should decrease. This experiment did not work unfortunately; possibly do to 
sensitivity of the plate reader. 
The results of the cell-based ELISA assay contradict those reported earlier 
(Saito et al., 1999). Saito et al. found that up to 50% of MCHRl internalized after 30 
minutes ofMCH treatment. We were unable to observe the level ofMCHRl 
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internalization observed in their study even with the addition of GRKs. Even if we 
did observe 50% of MCHRl internalizing, it does not account for the near 100% level 
of desensitization we see in the ERK pathway. This suggests that another method of 
desensitization must be responsible for MCHRl desensitization. 
What makes this portion of this study significant is that the .desensitization of 
MCHRl seems to be over simplified or poorly understood. The only explanation for 
desensitization is internalization and it seems that the internalization is not always 
observed. Again, an alternative mechanism must be responsible for the 
desensitization of the ERK pathway following MCHRl activation. 
GRK2 is at least partially responsible for MCHRl-mediated ERK Desensitization 
It was hypothesized that phosphorylation ofMCHRl by GRK2 may be responsible 
for the observed desensitization of ERK. Phosphorylation could detach G proteins 
from the receptor or cause a conformational change that would alter the binding of 
MCH. GRK2 has already been determined to be necessary for P2-adrengergic 
receptor desensitization (Kong et al. , 1994). 
In addition to interacting with GPCRs, GRK2 has recently been shown to act 
directly onto the ERK pathway to decrease ERK activation. Overexpression of 
GRK2 has been shown to limit ERK activation in chemokine signaling which occurs 
through GPCRs. The limited ERK activation is independent of GPCR 
phosphorylation as mutant GRK2 that has lost its kinase ability still decreases ERK 
activation. If the GRK2 binding domains to Ga and Gpyare malfunctioned, GRK2 
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fails to inhibit ERK activation. This suggests that GRK2 is activated downstream of 
G protein signaling to inactivate the ERK pathway (Jimenez-Sainz et al. , 2006). 
To determine if GRK2 is responsible for MCHRl-mediated ERK 
desensitization, BHK-570 cells cotransfected with MCHRl and GRK2-K220L were 
treated twice with MCH (Figure 9). Following the second treatment, we observed 
similar ERK activation as the first. This is unlike our previous experiments without 
GRK2-K220L because the desensitization of the ERK pathway is not being observed. 
Literature supports two different roles of GRK2 in signal desensitization. One 
is that GRK2 acts at the receptor level to prevent further signaling. The D3 dopamine 
receptor is suggested to require phosphorylation by GRK2 to cause a conformational 
change that either decreases hormone binding or disrupts signal transduction 
(Kuzhikandathil et al., 2004). ~-Adrenergic receptor requires GRK.2 for proper 
desensitization of cAMP signaling (Kong et al., 1994). This is significant because it 
shows how GRK2 can be related in the desensitization in pathways other than ERK. 
The role of GRK2 desensitizing the ERK pathway directly is another role of 
GRK2 in desensitization. Jimenez-Sainz et al. has shown that GRK.2 is activated by 
G proteins and that overexpression of GRK2 is responsible for decreasing ERK 
activation (Jimenez-Sainz et al., 2006). This shows that GRK2 can act directly on the 
ERK pathway to desensitize it. Supporting data shows that a GRK.2 dominant 
negative increases ERK signaling in mice (Fu et al., 2013). 
These two types of literature regarding GRK.2 shows that it is responsible for 
desensitization ofGPCR signaling with other receptors. MCHRl can reasonably rely 
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on GRK2 to desensitize the receptors or its downstream pathways. Our results show 
that the ERK pathway cannot desensitize to MCH without GRK2 so this molecule is 
at least involved in desensitization. It is significant to find suggestions for an 
alternative mechanism of MCH desensitization because the previous mode of 
internalization does not seem to explain the substantial ERK desensitization. A future 
direction regarding GRK2 would be to determine if it acts directly on MCHRl or on 
the ERK pathway to cause the observed desensitization of the pathway following 
MCH signaling (Figure 12). If a precise mechanism can be determined, we would be 
at a stage where new therapeutics could be produced to mimic the actions of GRK2 
related to MCH signaling and potentially treat some of the conditions related to 
overactive MCH signaling. 
Determining if ERK Desensitization is Homologous or Heterologous 
There are two types of pathway desensitization, homologous and heterologous. 
Homologous desensitization means that the desensitization is agonist specific or that 
only one type of receptor is prevented from activating the pathway. In heterologous 
desensitization, multiple types of receptors are prevented from activating a pathway 
(Chuang, 1996). Observing the desensitization profile of other activators of ERK 
could indirectly shed light onto whether homologous or heterologous desensitization 
is being observed following MCHRl activation. If the profile is similar, it suggests 
the desensitization of the ERK pathway would be heterologous. This would imply 
that GRK2 acts on the pathway level rather than at the receptor level. Likewise, if the 
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Does GRK2 act at the Receptor Level or 
Pathway Level? 
Rece tor Activation 
Gpreins'\. 
ERK I GRK2 
Pathway " MCHRl 
Desensitization? 
Figure 12: Diagram to show how GRK2 could potential desensitize 
the ERK signaling pathway to MCH. GRK2 could cause 
desensitization by acting directly on MCHRl or by acting at the 
pathway level within the ERK pathway. 
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desensitization profile is different, it suggests the pathway is undergoing homologous 
desensitization and that GRK2 is likely acting at the receptor level. 
We decided to activate ERK again with MCH, but this time through MCHR2, 
and by using isoproterenol (Figures 10 and 11). We determined that in both cases, 
ERK desensitizes in a similar manner as is observed when MCHRl is activated. This 
implies that the pathway is undergoing heterologous desensitization. This goes 
against some literature as insulin has been shown to induce homologous 
desensitization of the ERK pathway (Fucini, 1999). However, insulin does not signal 
through a GPCR as MCH and isoproterenol do so this might account for the 
difference (Ullrich et al., 1985). 
To gain confidence that MCHRl activation induces heterologous ERK 
desensitization, several experiments could be performed. One that we tried was to 
stimulate the pathway with one agonist followed by a second agonist 30 minutes later 
to observe if the pathway was desensitized to the different agonist. If ERK activation 
was observed, then the pathway would likely be in homologous desensitization. If 
the pathway cannot be activated it is likely in heterologous desensitization. When 
this experiment was conducted, Western Blotting difficulties were encountered. 
An alternate explanation for suggesting that the ERK pathway is undergoing 
heterologous desensitization is that it may just be chance that the other stimuli have a 
similar desensitization profile. Suggesting heterologous desensitization is largely 
based on assumptions and probability and cannot be said with much confidence until 
other experiments are performed. It is possible that MCHRl, MCHR2, and 
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isoproterenol simply cause similar ERK desensitization profiles by chance and not 
because the pathway is in heterologous desensitization. 
There are several general concerns about this study. The main concern is the 
lack of repeated experiments. For the most part, each experiment was only conducted 
once which means any conclusions are just suggestions at best. To further prove any 
of the conclusions in this study, each experiment needs to be conducted with similar 
results several more times. The primary future direction of this study will be to 
increase the number of experiments conducted so that the conclusions can be further 
supported. 
The recent news that MCHRl is potentially only activated in the neurons of 
the lateral hypothalamus has limited the physiological importance of using 3T3-Ll 
preadipocytes as the endogenous cell model. While this preadipocyte cell line does 
naturally express MCHRl, the existence of the receptor may just be in small basal 
level amounts or even the remnants of an ancestor whose original function is lost. 
While a preadipocyte does not appear to be a perfect model anymore, it still could be 
physiologically relevant if MCHRl desensitizes in preadipocytes in the same manner 
as neurons which will need to be tested in the future. 
Finally, a major future direction regarding this study is to pinpoint the role of 
GRK2 in MCHRl mediated ERK desensitization. It was hypothesized that the kinase 
activity of GRK2 could phosphorylate MCHRl which could be enough for 
desensitization. The phosphate group could prevent G proteins from binding to the 
receptor or cause a conformational change in the extracellular region of MCHRl that 
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could decrease its affinity for MCH. Jimenez-Sainz et al. has shown that the presence 
of GRK2 decreases the level of ERK activation (Jimenez-Sainz et al., 2006). 
Therefore, another possibility is that MCHRl could activate GRK2 by G protein 
signaling which then shuts down ERK activation. In either case, the most significant 
conclusion for this study is that GRK.2 plays a role in MCHRl-mediated ERK 
desensitization and with further mechanistic study, this knowledge could lead to new 
therapeutics. 
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